Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 1:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: breast irradiation Clear all
Terminated Phase 2 Interventional

Brachytherapy Radiation Directly to the Liver in Breast Cancer Patients With Metastatic to Liver

NCT00891800
View directory record Official record
Conditions
Breast Cancer Metastatic to the Liver
Interventions
Brachytherapy, SIR-Sphere
Device
Lead sponsor
St. Joseph's Hospital, Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 6, 2011 · Synced Sep 29, 2026, 1:27 AM EDT
Withdrawn Phase 2 Interventional

Ixabepilone and SBRT For Metastatic Breast Cancer

NCT01818999
View directory record Official record
Conditions
METASTATIC BREAST CANCER
Interventions
IXABEPILONE, STEREOTACTIC BODY RADIATION THERAPY
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 1 Interventional

Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer

NCT03958721
View directory record Official record
Conditions
Resistant Breast Cancer, Non-metastatic Invasive Breast Cancer
Interventions
Capecitabine, Radiotherapy
Drug · Radiation
Lead sponsor
A Bapsi Chakravarthy, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 26, 2023 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Not applicable Interventional

Demonstration of a Novel Approach Using Surface-Image Guidance to Improve Delivery of Breast Radiotherapy

NCT03799523
View directory record Official record
Conditions
Breast Cancer
Interventions
Temporary skin markings, Surface imaging
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

NCT00066690
View directory record Official record
Conditions
Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions
Exemestane, Laboratory Biomarker Analysis, Oophorectomy, Quality-of-Life Assessment, Radiation Therapy, Tamoxifen, Triptorelin
Drug · Other · Procedure + 1 more
Lead sponsor
ETOP IBCSG Partners Foundation
Network
Eligibility
18 Years to 65 Years · Female only
Enrollment
3,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2024
U.S. locations
480
States / cities
Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 323 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 1 Interventional

Study of ST266 Versus Saline in Treating Skin Irritation From Radiation

NCT01714973
View directory record Official record
Conditions
Radiation-induced Dermatitis
Interventions
ST266
Biological
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2019 · Synced Sep 29, 2026, 1:27 AM EDT
Recruiting Not applicable Interventional

Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences

NCT04650256
View directory record Official record
Conditions
Skin Toxicity
Interventions
Complementary and alternative medicine (CAM)
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Early Phase 1 Interventional

Radiation Therapy in Treating Women With Invasive Breast Cancer

NCT00301041
View directory record Official record
Conditions
Breast Cancer
Interventions
laboratory biomarker analysis, adjuvant therapy, radiation therapy
Other · Procedure · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Sep 29, 2026, 1:27 AM EDT
Not listed Phase 2 Interventional

Accelerated Partial Breast Radiotherapy With Either Mammosite or Intensity Modulated Radiotherapy

NCT01185145
View directory record Official record
Conditions
Breast Cancer
Interventions
Breast Brachytherapy with Mammosite RTS, Intensity Modulated Radiotherapy
Radiation
Lead sponsor
Rocky Mountain Cancer Centers
Other
Eligibility
40 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2024
U.S. locations
6
States / cities
Aurora, Colorado • Boulder, Colorado • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Not applicable Interventional

Healing Touch, Quality of Life, and Immunity During Breast Cancer Treatment

NCT00565305
View directory record Official record
Conditions
Breast Cancer
Interventions
Healing Touch, Standard Treatment
Behavioral · Radiation
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 95 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Sep 29, 2026, 1:27 AM EDT
Active, not recruiting Not applicable Interventional

Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial

NCT02603341
View directory record Official record
Conditions
Breast Cancer
Interventions
Photon, Proton
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years and older
Enrollment
1,238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2036
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Not applicable Interventional

Intraoperative Radiation Therapy in Early Stage Breast Cancer

NCT02266602
View directory record Official record
Conditions
Breast Cancer
Interventions
Intraoperative Radiation Therapy
Radiation
Lead sponsor
Benaroya Research Institute
Other
Eligibility
45 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Sep 29, 2026, 1:27 AM EDT
Recruiting No phase listed Observational

GammaPod Registry and Quality of Life Nomogram

NCT03562273
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Quality Of Life Sizing Nomogram
Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
4
States / cities
Bel Air, Maryland • Columbia, Maryland • Glen Burnie, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 29, 2026, 1:27 AM EDT
Terminated No phase listed Observational

Predictive Blood Tests for Severe Radiation Reactions in Breast Cancer Patients

NCT00652678
View directory record Official record
Conditions
Abnormalities, Radiation-Induced
Interventions
Not listed
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
48 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 2 Interventional

Tangential Radiation Therapy Without Axillary Dissection in Breast Cancer

NCT00165243
View directory record Official record
Conditions
Early-Stage Breast Cancer
Interventions
Tangential radiation
Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
55 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Sep 29, 2026, 1:27 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor

NCT06154590
View directory record Official record
Conditions
Metastatic Breast Cancer, Tumor, Muscle Neoplasms, Chronic Pain
Interventions
Method(s)1 Attribution, Method(s)2 Attribution,
Drug
Lead sponsor
DR. DIANE CHISESI NFS. MD. PHD.
Other
Eligibility
44 Years to 59 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Sep 29, 2026, 1:27 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

NCT06136897
View directory record Official record
Conditions
Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Pertuzumab, Radiologic Examination, Trastuzumab
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 29, 2026, 1:27 AM EDT
Recruiting No phase listed Observational

The PREDICT Registry:

NCT03448926
View directory record Official record
Conditions
DCIS, Stage 0 Breast Cancer, Ductal Breast Carcinoma In Situ
Interventions
Treatment recommendation surveys, 7-gene biosignature
Other · Device
Lead sponsor
PreludeDx
Industry
Eligibility
30 Years to 85 Years · Female only
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
30
States / cities
Scottsdale, Arizona • La Jolla, California • San Mateo, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 29, 2026, 1:27 AM EDT
Terminated Not applicable Interventional Results available

Conformal High Dose Intensity Modulated Radiation Therapy for Disease to Thoracic and Lumbar Spine

NCT01654068
View directory record Official record
Conditions
Vertebral Metastasis
Interventions
Conformal High Dose Intensity Modulated Radiation Therapy
Radiation
Lead sponsor
Ronald McGarry
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Results available

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

NCT01796197
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab, Pertuzumab, Paclitaxel, Doxorubicin, Cyclophosphamide, Mastectomy, Radiation Therapy
Drug · Procedure · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ

NCT00438659
View directory record Official record
Conditions
Breast Cancer, Dermatologic Complications, Radiation Toxicity, Skin Reactions Secondary to Radiation Therapy
Interventions
mometasone furoate, placebo
Drug · Other
Lead sponsor
North Central Cancer Treatment Group
Network
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
189
States / cities
Aurora, Illinois • Bloomington, Illinois • Canton, Illinois + 116 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2016 · Synced Sep 29, 2026, 1:27 AM EDT
Recruiting Not applicable Interventional

SABER Study for Selected Early Stage Breast Cancer

NCT04360330
View directory record Official record
Conditions
Breast Cancer, Early-stage Breast Cancer
Interventions
Stereotactic Ablative Breast Radiotherapy
Radiation
Lead sponsor
University of Miami
Other
Eligibility
50 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 29, 2026, 1:27 AM EDT
Completed Not applicable Interventional

Image Guided Radiotherapy (IGRT) for Prone Partial Breast Irradiation

NCT02272400
View directory record Official record
Conditions
Breast Cancer
Interventions
IGRT for prone partial breast irradiation (PBI)
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Sep 29, 2026, 1:27 AM EDT
Active, not recruiting Phase 2 Interventional

Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy

NCT03768492
View directory record Official record
Conditions
Carcinoma Breast
Interventions
Caffeine anhydrous 5% added to Lipoderm Cream Base., Lipoderm Cream Base
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 29, 2026, 1:27 AM EDT